5002-47-1
5002-47-1
Chemical Structure
Fluphenazine decanoate
- CAS No.: 5002-47-1
- Formula:C32H44F3N3O2S
- Molecular Weight:591.77
IUPAC Name: 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethyl decanoate
InChIKey: VIQCGTZFEYDQMR-UHFFFAOYSA-N
SMILES: CCCCCCCCCC(OCCN1CCN(CCCN2C3=C(C=CC=C3)SC4=CC=C(C(F)(F)F)C=C24)CC1)=O
Biological Activity: Fluphenazine decanoate is a CNS-penetrant dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fluphenazine decanoate | 98.75% | Fluphenazine decanoate is a CNS-penetrant dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fluphenazine decanoate (Standard) | ≥98% | Fluphenazine decanoate (Standard) is the analytical standard of Fluphenazine decanoate. This product is intended for research and analytical applications. Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.99
HY-B1904BFluphenazine decanoate hydrochloride -
Similarity Score 0.98
HY-B1904AFluphenazine decanoate dihydrochloride -
Similarity Score 0.98
HY-Z8165Fluphenazine decanoate impurity 6 -
Similarity Score 0.97
HY-Z8166Fluphenazine decanoate impurity 7 -
Similarity Score 0.96
HY-Z8164Fluphenazine decanoate impurity 5 -
Similarity Score 0.95
HY-107947Fluphenazine enanthate -
Similarity Score 0.94
HY-Z8163Fluphenazine decanoate impurity 3 -
Similarity Score 0.87
HY-W719480Fluphenazine decanoate impurity 8 -
Similarity Score 0.87
HY-W712157Fluphenazine decanoate impurity 9 -
Explore the MedChemAI to find more analogs
References
- [1]. Goodwin DG, et al. Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J Parasitol. 2011 Feb;97(1):148-51. [Content Brief]
- [2]. Lifshitz K, et al. Effects of dopamine agonists on Cebus apella monkeys with previous long-term exposure to fluphenazine. Biol Psychiatry. 1997 Mar 15;41(6):657-67. [Content Brief]
- [3]. Stoessl AJ, et al. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. Psychopharmacology (Berl). 1989;98(3):372-9. [Content Brief]
